PB 357Alternative Names: PB357
Latest Information Update: 22 Mar 2016
At a glance
- Originator Pfizer
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 22 Mar 2016 PB 357 is still in phase I trials for Cancer in USA
- 31 Aug 2011 Phase-I clinical trials in Cancer in USA (PO)